TXA Nebulization

Phase 3Small molecule

PPost Graduate Institute of Medical Education and Research, Chandigarh

TXA Nebulization is one of 4 small molecule programs targeting Hemoptysis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemoptysisActive, not recruiting

HemoptysisPhase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Hemoptysis

#DrugCompanyPhaseTrials

Adrenaline

SSamson Clinical Operations Pty Ltd

Cyklokapron

4 3

Glypressin

MMallinckrodt

Phase 3

1 4

TXA Nebulization

PPost Graduate Institute of Medical Education and Research, Chandigarh

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemoptysis1 trial

TXA Nebulization for the Treatment of Hemoptysis

Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT05648656·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TXA Nebulization. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TXA Nebulization compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TXA Nebulization. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Post Graduate Institute of Medical Education and Research, Chandigarh company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPost Graduate Institute of Medical Education and Research, Chandigarh

TXA Nebulization

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hemoptysis1 trial

References

Drug Info

Quick Facts

Related News